Genetic Polymorphisms in the HTR2C and Peroxisome Proliferator-Activated Receptors Are Not Associated with Metabolic Syndrome in Patients with Schizophrenia Taking Clozapine
Shi Hyun Kang, Jong Il Lee, An Kee Chang, Yeon Ho Joo, Chang Yoon Kim, Seong Yoon Kim
Psychiatry Investig. 2011;8(3):262-268.   Published online 2011 May 26     DOI: https://doi.org/10.4306/pi.2011.8.3.262
Clinical, Biochemical and Genetic Variables Associated With Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders Using Second-Generation Antipsychotics: A Systematic Review
Marius H. Sneller, Nini de Boer, Sophie Everaars, Max Schuurmans, Sinan Guloksuz, Wiepke Cahn, Jurjen J. Luykx
Frontiers in Psychiatry.2021;[Epub]     CrossRef
Serum peroxisome proliferator-activated receptor-gamma levels in acute phase of male patients with schizophrenia and their relationship with metabolic parameters
Tevfik Kalelioglu, Nurdan Durak, Nesrin Karamustafalioglu, Abdullah Genc, Mustafa Akkus, Akif Tasdemir, Cem Mehmet Ilnem
Psychiatry and Clinical Psychopharmacology.2017; 27(1): 30.     CrossRef
Genetic variants impacting metabolic outcomes among people on clozapine: a systematic review and meta-analysis
Rachel J. Suetani, Dan Siskind, Heidi Reichhold, Steve Kisely
Psychopharmacology.2017; 234(20): 2989.     CrossRef
A systematic review of genetic variants associated with metabolic syndrome in patients with schizophrenia
Stefanie Malan-Müller, Sanja Kilian, Leigh L. van den Heuvel, Soraya Bardien, Laila Asmal, Louise Warnich, Robin A. Emsley, Sîan M.J. Hemmings, Soraya Seedat
Schizophrenia Research.2016; 170(1): 1.     CrossRef
Pharmacogenetics of clozapine response and induced weight gain: A comprehensive review and meta-analysis
Florence Gressier, Stefano Porcelli, Raffaella Calati, Alessandro Serretti
European Neuropsychopharmacology.2016; 26(2): 163.     CrossRef
Prevalence and risk factors of metabolic syndrome among drug-naive psychotic patients
Nagy Fawzy, AmanyEl Shabrawy, Amira Youssef
Egyptian Journal of Psychiatry.2015; 36(2): 101.     CrossRef
HTR2Cpolymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: A meta-analysis
Xiaojie Ma, Tuerxun Maimaitirexiati, Rong Zhang, Xueping Gui, Wenhui Zhang, Guozheng Xu, Gang Hu
International Journal of Psychiatry in Clinical Practice.2014; 18(4): 229.     CrossRef
No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain
Eva J. Brandl, Arun K. Tiwari, Clement C. Zai, Nabilah I. Chowdhury, Jeffrey A. Lieberman, Herbert Y. Meltzer, James L. Kennedy, Daniel J. Müller
Psychiatry Research.2014; 219(2): 255.     CrossRef
Pharmacogenetics of Second-Generation Antipsychotics
Mark D Brennan
Pharmacogenomics.2014; 15(6): 869.     CrossRef
Genetics of Antipsychotic-Induced Weight Gain: Update and Current Perspectives
Amy CC Kao, Daniel J Müller
Pharmacogenomics.2013; 14(16): 2067.     CrossRef
Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy
C. Anthony Altar, John Hornberger, Ashwini Shewade, Victor Cruz, Jill Garrison, David Mrazek
International Review of Psychiatry.2013; 25(5): 509.     CrossRef
Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Pro12Ala
Julia Staeker, Stefan Leucht, Werner Steimer
Molecular Diagnosis & Therapy.2012; 16(2): 93.     CrossRef